The FDA has set a review date and scheduled an advisory committee meeting for uniQure’s high-profile Huntington’s disease gene therapy, pushing the program toward a potential decision by May 1. The update keeps the therapy in the spotlight as the company prepares for what would be one of the sector’s most closely watched gene-therapy determinations.